Platelet recovery and survival data for each antibody combination using COST software
| . | Antibody combination . | ||||
|---|---|---|---|---|---|
| Unsensitized . | B2G1Δnab . | B2G1Δnab90* . | B2G1Δnab75* . | B2G1 . | |
| N | 12 | 7 | 3 | 5 | 8 |
| COST data, mean ± SD | |||||
| Recovery | 55% ± 12% | 56% ± 17% | 54% ± 20% | 53% ± 8% | 52% ± 16% |
| Survival | 189 ± 45 h | 196 ± 50 h | 58 ± 12 min | 44 ± 4 min | 18 ± 5 min |
| P > .25 | P = .06 | ||||
| P < .01 | |||||
| P < .01 | |||||
| . | Antibody combination . | ||||
|---|---|---|---|---|---|
| Unsensitized . | B2G1Δnab . | B2G1Δnab90* . | B2G1Δnab75* . | B2G1 . | |
| N | 12 | 7 | 3 | 5 | 8 |
| COST data, mean ± SD | |||||
| Recovery | 55% ± 12% | 56% ± 17% | 54% ± 20% | 53% ± 8% | 52% ± 16% |
| Survival | 189 ± 45 h | 196 ± 50 h | 58 ± 12 min | 44 ± 4 min | 18 ± 5 min |
| P > .25 | P = .06 | ||||
| P < .01 | |||||
| P < .01 | |||||
B2G1Δnab90 and -75 denote platelet sensitized with a combination of 90% B2G1Δnab/10% B2G1 and 75% B2G1Δnab/25% B2G1, respectively. For unsensitized and B2G1Δnab-sensitized platelets which showed identical kinetics with a plateau phase during the first 24 hours (see Figure 1), the 24-hour time point was used as the first point for the curve fitting in the COST program. For B2G1-sensitized platelets and platelets sensitized with a combination of 75% B2G1Δnab/25% B2G1 and 90% B2G1Δnab/10% B2G1, where rapid destruction was observed without a plateau phase (see Figure 1), the 5-minute time point was used (see “Results”).